LCT updates Diabecell trial
Wednesday, 11 February, 2009
Auckland’s Living Cell Technologies (LCT) has reported long-term follow-up results from seven patients implanted with its porcine islet product Diabecell in a Phase I/IIa trial in Russia.
Five patients who received double low-dose implants showed no safety concerns and maintained good blood glucose control. The other two patients on a single higher-dose implant also reported no safety concerns, the company said.
LCT’s medical director Professor Bob Elliott said none of the patients had problems with clinically relevant episodes of low blood glucose.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
